Abstract: Fluorinated diaminobutane compounds in vivo are inhibitors of gamma-aminobutyric acid transaminase and have the following formula: ##STR1## wherein: R.sub.1 represents hydrogen, C.sub.1 -C.sub.6 alkyl, or phenyl-(C.sub.1 -C.sub.4 alkyl);R.sub.2 represents hydrogen, C.sub.1 -C.sub.6 alkyl, phenyl-(C.sub.1 -C.sub.4 alkyl), or R.sub.4, where R.sub.4 is as defined below;R.sub.3 represents hydrogen, or, except when R.sub.2 represents R.sub.4, R.sub.4, where R.sub.4 is as defined below;each R.sub.4, independently, represents C.sub.2 -C.sub.5 alkylcarbonyl, phenylcarbonyl, phenyl-(C.sub.1 -C.sub.4 alkyl) carbonyl, or an aminocarboxylic acid residue derived by removal of an hydroxy group from the carboxy moiety of an L-aminocarboxylic acid; andp represents 1 or 2,and pharmaceutically acceptable acid addition salts thereof.

Abstract: N-(1,3-dithiolan-2-ylidene)-4-alkylanilines are useful as anti-inflammatory agents, as analgesic agents and as antiasthmatic agents. The compounds involved can be prepared by the reaction of an appropriate 4-alkylaniline with a methyl(1,3-dithiolan-2-ylidene)sulfonium salt or with carbon disulfide and ethylene dibromide in the presence of a base.

Abstract: The present invention refers to a chlorine containing antibiotic substance, named antibiotic A/16686 factor A.sub.2, in an essentially pure form. The invention also relates to the process for the production of antibiotic A/16686 factors A.sub.2 by cultivation of an Actinoplanes strain and to the co-produced antibiotic A/16686 factos A.sub.1 and A.sub.3. Antibiotic A/16686 factors A.sub.1, A.sub.2 and A.sub.3 as well as the corresponding non-toxic physiologically acceptable acid addition salts are antimicrobial agents particularly active against gram-positive bacteria.

Abstract: Novel fluorinated alkenylene diamine derivatives are inhibitors of ornithine decarboxylase enzyme and have the following general Formula I: ##STR1## wherein: R.sub.c represents hydrogen or --COR.sub.5, where R.sub.5 is as defined below;R.sub.1 represents hydrogen or C.sub.1 -C.sub.6 alkyl;one of R.sub.2 and R.sub.3 represents hydrogen and the other represents C.sub.1 -C.sub.6 alkyl.R.sub.5 represents hydroxy or C.sub.1 -C.sub.8 alkoxy; andp represents 1 or 2.

Abstract: Novel fluorinated diamino-heptene and-heptyne derivatives are inhibitors of ornithine decarboxylase enzyme involved in polyamine formation and have the following general Formula I: ##STR1## wherein: Y represents CH.sub.2 .dbd.CH-- or CH.tbd.C--; andp represents 1 or 2.

Abstract: Compounds of the formula: ##STR1## wherein: X is fluorine, chlorine, or bromine;R is the group R.sub.2 as defined below;R.sub.1 is a group of the formula: ##STR2## or the group R.sub.2 as defined below; wherein R.sub.2 is: ##STR3## wherein R.sub.3 is hydrogen, (C.sub.1 -C.sub.4)alkyl, or (C.sub.1 -C.sub.4)alkoxy, andR.sub.4 is (C.sub.1 -C.sub.4)alkyl or (C.sub.1 -C.sub.4)alkoxy;or a (C.sub.1 -C.sub.8)alkyl ester thereof; or a non-toxic pharmaceutically acceptable salt thereof, inhibit MAO in vivo and can be administered either alone or in combination with an aromatic L-amino acid decarboxylase inhibitor for the treatment of depression.

Abstract: Sustained release formulations for the anorectic agent, diethylpropion hydrochloride, are disclosed which are suitable for use in capsules.

Abstract: Fluorinated aminobutyric acid and diaminobutane compounds in vivo are inhibitors of gamma-aminobutyric acid transaminase and have the following formula: ##STR1## wherein: Y represents hydrogen or fluorine;Z represents --CH.sub.2 NR.sub.1 R.sub.2, where R.sub.1 and R.sub.2 are as defined below, or --COR.sub.3 where R.sub.3 is as defined below;R.sub.a represents hydrogen or R.sub.4, where R.sub.4 is as defined below;R.sub.1 represents hydrogen, C.sub.1 -C.sub.6 alkyl or phenyl-(C.sub.1 -C.sub.4 alkyl);R.sub.2 represents hydrogen, C.sub.1 -C.sub.6 alkyl, phenyl-(C.sub.1 -C.sub.4 alkyl) or, when R.sub.a is hydrogen, R.sub.4, where R.sub.4 is as defined below;R.sub.3 represents hydroxy, or when R.sub.a is hydrogen, C.sub.1 -C.sub.8 alkoxy, --NR.sub.5 R.sub.6, where R.sub.5 and R.sub.6 are as defined below, or an aminocarboxylic acid residue derived by removal of an hydrogen atom from the amino moiety of an L-aminocarboxylic acid;each R.sub.4, independently, represents C.sub.2 -C.sub.

Abstract: The use of novel imidazolecarboxylic acid derivatives of the following general structure which are useful as antihypertensives, cardiotonics and antithrombotics ##STR1## wherein Q and T are an oxygen or sulfur atom; R is hydrogen, lower alkyl, lower alkylcarbonyl or benzoyl; R.sub.1 is hydrogen or --CH(R.sub.3)R.sub.4 ; R2 is lower alkoxy, phenoxy or phenoxy substituted at the ortho, meta, or para position with lower alkyl, lower alkoxy, hydroxy, halogen, trifluoromethyl, lower alkylthio, lower alkylsulfone, or lower alkylsulfoxide; R.sub.3 is hydrogen or lower alkyl; R.sub.4 is hydrogen, hydroxy, lower alkoxy, lower alkylcarbonyl, --ONO.sub.2 or halogen; and their pharmaceutically acceptable salts thereof.

Abstract: 2-Amino-3-(3'-hydroxyphenyl)-3-butenoic acid or 2-amino-3-(3', 4'-dihydroxyphenyl)-3-butenoic acid can be used to treat depression either alone or in combination with an extracerebrally acting AADC inhibitor.

Abstract: This invention relates to 2-(difluoromethyl)-2,5-diaminopentanoic acid, or a pharmaceutically acceptable acid addition salt thereof, and to the methods for the preparation and use thereof.

Abstract: A process for preparing 16.alpha.-hydroxy-17.alpha.-aminopregnane derivatives through the opening of the corresponding 16.alpha., 17.alpha.-epoxides with amines.The use of the thus obtained compounds as intermediates in the synthesis of pharmacologically active pregnano-[17.alpha.,16.alpha.-d]oxazolines is also claimed.

Abstract: 3H-naphth[1,2-d]imidazole derivatives of formula ##STR1## wherein R stands for hydrogen, methyl or ethyl, R.sub.1 represents hydrogen, methyl or ethyl, R.sub.2 represents hydrogen, methyl, ethyl, phenyl or substituted phenyl, the symbol R.sub.3 stands for a phenyl radical optionally substituted and R.sub.4 and R.sub.5, each independently, may represent hydrogen, halogen, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkylthio, (C.sub.1 -C.sub.4)alkoxy or halo-(C.sub.1 -C.sub.4)alkoxy, are described. Also described is the process for preparing the novel compounds, their use as antiinflammatory agents and the pharmaceutical compositions containing them.

Abstract: This invention relates to aroyl-2-imidazolidinones of the following general structure which are useful as cardiotonics and antihypertensive agents ##STR1## wherein Ar is furanyl, thienyl, 1H-pyrrolyl, or phenyl optionally substituted with one or two X groups; X is halogen, hydroxy, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulfoxide, lower alkylsulphone, trifluoromethyl, --SO.sub.2 N(R.sub.2).sub.2, NR.sub.3 R.sub.4, pyrrolidino, piperidino, morpholino, piperazino or N'-alkyl-piperazino; R is hydrogen, lower alkyl, lower alkylcarbonyl or benzoyl; each of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 is hydrogen or lower alkyl; T is an oxygen atom or a divalent sulfur atom; and the pharmaceutically acceptable salts thereof.

Abstract: Novel 4-aroylimidazol-2-ones of the following general structure which are useful as antihypertensives, cardiotonics, antithrombotics, bronchodilators and uterospasmolytics ##STR1## wherein Ar is 2-furyl, 2-thienyl or phenyl, the latter of which may optionally be substituted with one or two X groups; X is halogen, hydroxy, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, methylenedioxy, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulfoxide, C.sub.1-4 alkylsulfone, CF.sub.3, --SO.sub.2 N(R.sub.2).sub.2, NR.sub.3 R.sub.4, pyrrolidino, piperidino, morpholino, piperazino or N'-alkyl-piperazino, R is hydrogen, C.sub.1-4 alkyl, C.sub.1-4 alkylcarbonyl or benzyl; each of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are hydrogen or C.sub.1-4 alkyl; and the pharmaceutically acceptable salts thereof.

Abstract: Certain .alpha.-(fluoromethyl or difluoromethyl)-.alpha.-aminoacetonitriles are prepared by treating the appropriate .alpha.-(fluoromethyl or difluoromethyl) ketimine magnesium halide with hydrogen cyanide or with an alkali metal cyanide or ammonium cyanide and a proton source. The products are useful as intermediates for making .alpha.-(fluoromethyl or difluoromethyl)-.alpha.-amino acids having pharmacological activity.

Abstract: This invention relates to aroylimidazole-2-ones and their acid and base addition salts as well as their use as cardiotonics in the treatment of cardiac failure.

Abstract: An improved reagent and method for assay of total bilirubin in biological fluids utilizes diazo sulfanilic acid to convert bilirubin to azobilirubin which is then quantitatively measured. The improved reagent and method include the solvent accelerator tetramethylene sulfone. The use of tetramethylene sulfone as also allows the use of nonionic surfactants, obviating the need for serum blank correction in highly lipemic serum. Furthermore, the use of tetramethylene sulfone and nonionic surfactants renders the reagent mixture less viscous facilitating automated analysis.

Abstract: 1,7-Dihydro-pyrrolo[3,4-e][1,4]diazepin-2(1H)-ones of the formula ##STR1## wherein R is lower alkyl, R.sub.1 stands for hydrogen, methyl, ethyl or phenyl, R.sub.2 is hydrogen or lower alkyl and R.sub.3 is hydrogen, chloro, fluoro, bromo, trifluoromethyl or methoxy are described with anticonvulsant and anti-anxiety activity.Also described is the process for preparing the above compounds and pharmaceutical preparations containing them.

Abstract: Compounds of the formula ##STR1## wherein R is H, halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, 3,4-methylenedioxy, CF.sub.3, NO.sub.2, NH.sub.2, N(C.sub.1-4 alkyl).sub.2, CN, OH, --S(C.sub.1-4 alkyl) or --SO.sub.2 (C.sub.1-4 alkyl); R.sub.1 and R.sub.2 are independently each H or C.sub.1-4 alkyl or taken together with the attached N atom are morpholino, piperidino, pyrrolidino, piperazino, or N-- C.sub.1-4 -alkyl piperazino; and, when R is halo, C.sub.1-4 alkyl or C.sub.1-4 alkoxy, x is 0-3 and, otherwise, is 0 or 1;or a pharmaceutically acceptable salt thereof with an acid or for the compounds wherein R.sub.1 and R.sub.2 are both not H, a quaternary ammonium salt thereof with a C.sub.1-4 alkyl halidehave valuable antiviral activity, e.g., for treatment of infections caused by a herpes virus.